Work

Pnd32 Evaluation of Global Improvement and Lifetime Costs of Treating Tardive Dyskinesia Shows Treatment With Valbenazine Dominates Deutetrabenazine

Year: 2019

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2019.04.1305

Authors: M. Ganz, S. Stern, A. Chavan, M. Serbin, C. Yonan

Institution: Neurocrine Biosciences (United States)

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2953775388

Cites:

Cited by: 1

Related to: 10